Physician profile
Shashi Berdia
NPI 1881794998
$6,122.69
in general payments reported to CMS, 2019-2025
25 companies · $1,758 in 2025
The $1,758 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $85.65 · 2021: $1,029 · 2022: $845 · 2023: $883 · 2024: $1,301 · 2025: $1,758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,941.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $992.23 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Abbvie INC. | $811.52 | 2021-2025 | Qulipta, Ubrelvy |
| E.R. Squibb & Sons, L.L.C. | $770.18 | 2022-2025 | Cobenfy |
| Alexion Pharmaceuticals, INC. | $384.75 | 2021-2024 | Ultomiris |
| Ucb, INC. | $375.01 | 2023-2024 | Nayzilam, Rystiggo |
| Abbott Laboratories | $325.00 | 2023-2024 | Xience Sierra, Freestyle Libre 3 |
| Lundbeck LLC | $262.16 | 2020-2024 | Vyepti |
| Eisai INC. | $193.60 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $176.12 | 2019-2022 | |
| Indivior INC. | $159.41 | 2020-2025 | Sublocade |
| Neurocrine Biosciences, INC. | $154.70 | 2021-2025 | |
| Medtronic, INC. | $139.99 | 2025 | Percept PC Brainsense |
| 4web, INC. | $135.14 | 2022 | |
| Supernus Pharmaceuticals, INC. | $125.01 | 2024 | Qelbree |
| Amneal Pharmaceuticals LLC | $125.00 | 2025 | Crexont |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $125.00 | 2022 | |
| Amgen INC. | $124.97 | 2025 | |
| Axsome Therapeutics, INC. | $124.89 | 2025 | Sunosi |
| Acadia Pharmaceuticals INC | $124.77 | 2021 | |
| Jazz Pharmaceuticals INC. | $117.76 | 2024 | |
| Mylan Specialty L.P. | $114.78 | 2023 | Yupelri |
| Janssen Pharmaceuticals, INC | $94.12 | 2019-2020 | |
| Lilly USA, LLC | $76.39 | 2025 | Kisunla |
| Sunovion Pharmaceuticals INC. | $64.65 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $25.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shashi Berdia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.